Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine) -2 h infusion for 5 days - As first-line treatment for advanced low grade non- Hodgkin's lymphoma

European Journal of Cancer

Volumn 34, Issue 10, 1998, Pages 1560-1564

  Fridrik, M A ^a   Jager G ⁱ   Kienzer, H R ^b   Hausmaninger, H ^c   Oppitz, P ^d   Krieger, O ^e   Zabernigg, A ⁱ   Lang, A ^f   Neubauer, M ^g   Weidinger, G ⁱ   Schiller, L ^f   Seewann, H L ⁱ   Chott, A ^h   Linkesch, W ⁱ  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c GENERAL HOSPITAL   (Austria)

^d GENERAL HOSPITAL   (Austria)

^e ELISABETHINEN HOSPITAL   (Austria)

^f GENERAL HOSPITAL   (Austria)

^g Bh Brüder Hospital   (Austria)

^h UNIVERSITY OF VIENNA   (Austria)

ⁱ NONE

Author keywords

Chemotherapy; Intermediate grade; Low grade; Lymphoma; Non Hodgkin's treatment

Indexed keywords

CLADRIBINE;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTHRITIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAIR LOSS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 0032167887     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00140-3     Document Type: Article

References (20)

1. 1. Horning JS, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984, 311, 1471-1475.
2. 2. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980, 77, 6865-6869.
3. 3. Carson DA, Carrera DJ, Wasson DB, Yamanaka H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv Enzyme Reg 1988, 27, 395-404.
4. 4. Kay AC, Saven A, Carrera CJ, et al. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992, 10, 371-377.
5. 5. Lennert K, Feller AC. Histopathologie der Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassifikation). Berlin, Springer, 1990.
6. 6. Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 1987, 5, 1670-1672.
7. 7. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
8. 8. Miller AB, Hoogstraten B, Staquet N, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
9. 9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84, 1361-1392.
10. 10. Shipp MA. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329, 987-994.
11. 11. Betticher DC, Zucca E. Rohr A von, et al. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol 1996, 7, 793-799.
12. 12. Piro LD, Petroni G, Barcos M, Johnson J, Saven A, Peterson B. Cancer and leukemia group B: bolus infusion 2-chlorodeoxyadenosine (2-CdA) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL): CALGB 9153. Blood 1995, 86(Suppl. 1), abstract 1082.
13. 13. Solal-Céligny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996, 14, 514-519.
14. 14. Saven A, Emanuelle S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995, 86, 1710-1716.
15. 15. Betticher DC, Fy MF, von-Rohr A, et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CdA) therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann Oncol 1994, 5, 57-64.
16. 16. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995, 49, 135-142.
17. 17. Beutler E, Piro LD, Saven A, et al. 2-chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991, 5, 1-8.
18. 18. Price CGA, Rohatiner AZS, Steward W, et al. Interferon alpha-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer 1991, 27(Suppl. 4), 534-536.
19. 19. Kimby E, Björkholm M, Gahrton G, et al. Ann Oncol, 1994, 5(Suppl. 2), 67-71.
20. 20. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J 1978, 1, 533-537.